Olaparib
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4041 publications
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Living Guideline, Version 2026.1.0.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 27, 2026
Adjuvant olaparib for patients with germline BRCA-mutated, high-risk, HER2-negative early breast cancer: real-world data from a French early access program.
Journal: ESMO real world data and digital oncology
Published: October 25, 2026
VITAL-3D: Volumetric Single-Cell Quantification Reveals Microenvironment-Dependent Drug Responses in Breast Cancer.
Journal: bioRxiv : the preprint server for biology
Published: October 24, 2026
ABCB1-Mediated Olaparib Resistance in Cervical Cancer: Molecular Mechanisms and Therapeutic Strategies.
Journal: Journal of visualized experiments : JoVE
Published: October 17, 2026
Chronic Alcohol Exposure Induces Persistent DNA Damage Response Signaling and Sensitizes Breast Epithelial Cells to PARP Inhibition.
Journal: bioRxiv : the preprint server for biology
Published: October 01, 2026
Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a g BRCA1 ovarian cancer patient with an acquired PARPi resistance mutation in TP53BP1.
Journal: medRxiv : the preprint server for health sciences
Published: October 01, 2026
The circSNX6 restricts dengue virus replication in association with PARP1 and ferroptosis.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 30, 2026
PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer.
Journal: Journal for immunotherapy of cancer
Published: September 23, 2026
When treatment backbones differ: a cautionary note on pooling immunotherapy-poly (ADP-ribose) polymerase inhibitor trials in ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: September 19, 2026
Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers.
Journal: Current opinion in oncology
Published: September 19, 2026
Beyond Homologous Recombination: Functional Modules of Olaparib Resistance Revealed by CRISPR Screens.
Journal: International journal of molecular sciences
Published: September 16, 2026
Last Updated: 11/08/2026